ATAlexandra Teixeira

Alexandra Teixeira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Teixeira has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microfluidic Extraction of Extracellular Vesicle-Associated Nucleic Acids for Downstream Molecular Analysis

    by Teresa Lage, Daniela Macedo, Hugo Silva, Alexandra Teixeira, Diogo Moreira, Natália Fiorenza, Ramón Lago Lestón, Ana Vilar Lagares, Belém Sampaio-Marques, Lara Pierantoni, et al.

    Aim: To develop a microfluidic workflow for extracting extracellular vesicle (EV)-associated nucleic acids (NAs) from biofluids, such as blood plasma and serum, for downstream molecular analysis. Methods: Healthy serum and plasma samples were spiked with EVs obtained from Hec-1-A cells carrying defined mutations and characterized in accordance with MISEV guidelines. The spiked samples were then processed using either the standard centrifugation-based ExoGAG protocol or a microfluidic workflow. The latter combines ExoGAG mediated aggregation of EVs with mechanical entrapment of the resulting EV aggregates in a microfluidic filtration device (EVNA-chip). The retained material was washed and on-chip lysed to release its NA cargo. NAs were subsequently purified using a commercial silica column, producing an output suitable for molecular analysis through droplet digital PCR (ddPCR). Results: The EVNA-chip recovery yield was 42.0 ± 4.28% and 38.1 ± 1.46% for double-stranded DNA (dsDNA) and microRNA respectively. The recovered dsDNA remained compatible with ddPCR detection of the KRAS p.G12D variant (c.35G>A) and with the assessment of MSI-associated alterations using BAT25, BAT26, NR21, NR24, and MONO27. The method was demonstrated for pilot cohort of patients with endometrial cancer. The RNA workflow supported reverse transcription and was demonstrated for the quantification of miR-X, a potential marker of Fabry disease, using patient samples and healthy controls. Conclusion: Although recovery was lower than with the standard protocol, the centrifugation-free EVNA- chip workflow demonstrates the compatibility of the method with downstream NA molecular analyses and is advantageous for the development of an integrated, automated platform for EV-based liquid biopsy applications.

  • Open Access

    Advanced Microfluidics for Single Cell‐Based Cancer Research

    by Adriana Carneiro, Marta Aranda Palomer, Margarida Esteves, Carolina Rodrigues, José Maria Fernandes, Francisca Oliveira, Alexandra Teixeira, Carlos Honrado, Lorena Dieguez, Sara Abalde‐Cela, et al.

    Cancer remains one of the leading causes of mortality worldwide, accounting for ≈10 million deaths annually. Critically, it is metastasis and not the primary tumour that causes most of these deaths. Understanding the mechanisms behind cancer dissemination and therapy resistance is thus a pressing challenge. Traditional bulk tissue analyses have failed to capture the full spectrum of intra‐tumour heterogeneity and the dynamic interactions within the tumour microenvironment. Studying cancer at the single‐cell level allows unravelling the roles of rare subpopulations, cell–cell interactions, and spatial dynamics that govern tumour evolution, metastasis, and immune evasion. This review explores how recent advances in microfluidic technologies are transforming ability to model and study cancer at the single‐cell level. Cutting‐edge platforms are highlighted, including droplet microfluidics, single cell‐derived spheroids, and tumour‐chips, that enable physiologically relevant 3D cancer models. By integrating immune components, biosensing, and patient‐derived materials, these platforms hold promise for advancing drug screening, immunotherapy assessment, and personalised medicine. It is concluded by identifying key challenges and priorities for future work, which should focus on increasing model complexity, reproducibility, and integration of spatiotemporal multiomics to better dissect tumour heterogeneity and accelerate clinical translation.


  • Open Access

    Single cell-derived spheroids for real-time growth and metabolomic studies in breast cancer

    by Margarida Esteves, Francisca Oliveira, Alexandra Teixeira, Arantxa Ibáñez, Andrea Garcia-Lizarribar, Iratxe Madarieta, José Maria Fernandes, Carolina Rodrigues, Alar Ainla, Lorena Diéguez, et al.

    Breast cancer remains a leading cause of cancer-related mortality, with disease progression and metastasis posing significant challenges in treatment. Three-dimensional (3D) cancer models have emerged as valuable tools for studying cancer cell biology in a physiologically relevant microenvironment. Studying the tumour heterogeneity and metabolic adaptations at the single-cell level can be crucial to identify factors driving metastatic progression. Here, we present a novel approach to generate single cell-derived breast cancer spheroids using cell lines (MCF-7 and MCF-10A) within a decellularised adipose tissue extracellular matrix (adECM). Spheroid culture conditions were optimised with integrated plasmonic nanosensors (gold nanostars - GNSs), to enable real-time surface-enhanced Raman scattering (SERS)-based measurements. Our results demonstrated that spheroid growth kinetics and viability in adECM were comparable to commonly used animal-derived matrices, validating its use as a reproducible ECM hydrogel. We further show that the concentration of plasmonic nanosensors used was compatible with cell culture and enabled SERS detection of a model reporter, paving the way for label-free, non-destructive analysis of cancer cell metabolism. This platform offers a promising approach to study cancer progression, including metabolic adaptations, with potential applications in biomarker discovery and preclinical research.

  • Open Access

    Development of a Plasmonic Light Management Architecture Integrated within an Interface Passivation Scheme for Ultrathin Solar Cells

    by António J. N. Oliveira, Jennifer P. Teixeira, Maria S. Relvas, Alexandra Teixeira, André F. Violas, Kevin Oliveira, Sara Abalde‐Cela, Lorena Diéguez, Mariana D. Cortinhal, Pedro M. C. Barquinha, et al.

    In response to climate and resource challenges, the transition to a renewable and decentralized energy system is imperative. Ultrathin Cu(In,Ga)Se2 (CIGS)‐based solar cells are compatible with such transition due to their low material usage and improved production throughput. Despite the benchmark efficiency of CIGS technology, ultrathin configurations face efficiency drops arising from increased rear interface recombination and incomplete light absorption. Dielectric passivation schemes address rear interface recombination, but achieving simultaneous electrical and optical gains is crucial for thinning down the absorber. Plasmonic nanoparticles emerge as a solution, enhancing light interaction through resonant scattering. In the proposed architecture, the nanoparticles are encapsulated within a dielectric rear passivation layer, combining effective passivation and light trapping. A controlled deposition and encapsulation of individualized nanoparticles is achieved by an optimized process flow using microfluidic devices and nanoimprint lithography. With the developed plasmonic and passivated architecture, a 3.7 mA cm−2 short‐circuit current density and a 23 mV open‐circuit voltage improvements are obtained, leading to an almost 2% increase in light‐to‐power conversion efficiency compared to a reference device. This work showcases the developed architecture potential to tackle the electrical and optical downfalls arising from the absorber thickness reduction, contributing to the dissemination of ultrathin technology.


  • Open Access

    Isolation of acute myeloid leukemia blasts from blood using a microfluidic device

    by Alexandra Teixeira, Maria Sousa-Silva, Alexandre Chícharo, Kevin Oliveira, André Moura, Adriana Carneiro, Paulina Piairo, Hugo Águas, Belém Sampaio-Marques, Isabel Castro, et al.

    Multiparametric approach for the efficient isolation of acute myeloid leukemia blasts from blood in microfluidic platforms.


  • Will data analytics revolution finally bring SERS to the clinic?

    by Ahmed Y.F. Mahmoud, Alexandra Teixeira, Marta Aranda, Maria S. Relvas, Sergio Quintero, Maria Sousa-Silva, Alexandre Chícharo, Mengkun Chen, Mohadeseh Hashemi, Jason B. King, et al.


  • Open Access

    Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review

    by Alexandra Teixeira, Luís Carreira, Sara Abalde-Cela, Belém Sampaio-Marques, Anabela C. Areias, Paula Ludovico, Lorena Diéguez

    Acute myeloid leukemia (AML) comprises a group of hematologic neoplasms characterized by abnormal differentiation and proliferation of myeloid progenitor cells. AML is associated with poor outcome due to the lack of efficient therapies and early diagnostic tools. The current gold standard diagnostic tools are based on bone marrow biopsy. These biopsies, apart from being very invasive, painful, and costly, have low sensitivity. Despite the progress uncovering the molecular pathogenesis of AML, the development of novel detection strategies is still poorly explored. This is particularly important for patients that check the criteria for complete remission after treatment, since they can relapse through the persistence of some leukemic stem cells. This condition, recently named as measurable residual disease (MRD), has severe consequences for disease progression. Hence, an early and accurate diagnosis of MRD would allow an appropriate therapy to be tailored, improving a patient’s prognosis. Many novel techniques with high potential in disease prevention and early detection are being explored. Among them, microfluidics has flourished in recent years due to its ability at processing complex samples as well as its demonstrated capacity to isolate rare cells from biological fluids. In parallel, surface-enhanced Raman scattering (SERS) spectroscopy has shown outstanding sensitivity and capability for multiplex quantitative detection of disease biomarkers. Together, these technologies can allow early and cost-effective disease detection as well as contribute to monitoring the efficiency of treatments. In this review, we aim to provide a comprehensive overview of AML disease, the conventional techniques currently used for its diagnosis, classification (recently updated in September 2022), and treatment selection, and we also aim to present how novel technologies can be applied to improve the detection and monitoring of MRD.


  • Open Access

    Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients

    by Adriana Carneiro, Paulina Piairo, Alexandra Teixeira, Dylan Ferreira, Sofia Cotton, Carolina Rodrigues, Alexandre Chícharo, Sara Abalde-Cela, Lúcio Lara Santos, Luís Lima, et al.

    Gastrointestinal (GI) cancers constitute a group of highest morbidity worldwide, with colorectal cancer (CRC) and gastric cancer being among the most frequently diagnosed. The majority of gastrointestinal cancer patients already present metastasis by the time of diagnosis, which is widely associated with cancer-related death. Accumulating evidence suggests that epithelial-to-mesenchymal transition (EMT) in cancer promotes circulating tumor cell (CTCs) formation, which ultimately drives metastasis development. These cells have emerged as a fundamental tool for cancer diagnosis and monitoring, as they reflect tumor heterogeneity and the clonal evolution of cancer in real-time. In particular, EMT phenotypes are commonly associated with therapy resistance. Thus, capturing these CTCs is expected to reveal important clinical information. However, currently available CTC isolation approaches are suboptimal and are often targeted to capture epithelial CTCs, leading to the loss of EMT or mesenchymal CTCs. Here, we describe size-based CTCs isolation using the RUBYchip™, a label-free microfluidic device, aiming to detect EMT biomarkers in CTCs from whole blood samples of GI cancer patients. We found that, for most cases, the mesenchymal phenotype was predominant, and in fact a considerable fraction of isolated CTCs did not express epithelial markers. The RUBYchip™ can overcome the limitations of label-dependent technologies and improve the identification of CTC subpopulations that may be related to different clinical outcomes.


  • Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification

    by Lei Wu, Alexandra Teixeira, Alejandro Garrido-Maestu, Laura Muinelo-Romay, Luis Lima, Lúcio Lara Santos, Marta Prado, Lorena Diéguez


  • Open Access

    In Vitro Evaluation of Lipopolyplexes for Gene Transfection: Comparing 2D, 3D and Microdroplet-Enabled Cell Culture

    by Juan L. Paris, Filipe Coelho, Alexandra Teixeira, Lorena Diéguez, Bruno F. B. Silva, Sara Abalde-Cela

    Complexes combining nucleic acids with lipids and polymers (lipopolyplexes) show great promise for gene therapy since they enable compositional, physical and functional versatility to be optimized for therapeutic efficiency. When developing lipopolyplexes for gene delivery, one of the first evaluations performed is an in vitro transfection efficiency experiment. Many different in vitro models can be used, and the effect of the model on the experiment outcome has not been thoroughly studied. The objective of this work was to compare the insights obtained from three different in vitro models, as well as the potential limitations associated with each of them. We have prepared a series of lipopolyplex formulations with three different cationic polymers (poly-l-lysine, bioreducible poly-l-lysine and polyethyleneimine), and assessed their in vitro biological performance in 2D monolayer cell culture, 3D spheroid culture and microdroplet-based single-cell culture. Lipopolyplexes from different polymers presented varying degrees of transfection efficiency in all models. The best-performing formulation in 2D culture was the polyethyleneimine lipopolyplex, while lipoplexes prepared with bioreducible poly-l-lysine were the only ones achieving any transfection in microdroplet-enabled cell culture. None of the prepared formulations achieved significant gene transfection in 3D culture. All of the prepared formulations were well tolerated by cells in 2D culture, while at least one formulation (poly-l-lysine polyplex) delayed 3D spheroid growth. These results highlight the need for selecting the appropriate in vitro model depending on the intended application.